Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”

Ann Oncol 2014; 25: 592–598 (doi: 10.1093/annonc/mdt543)

In the original article, the disclosure was incomplete. This has now been updated to add the statement for J. Baselga:

JB is the consultant and on the advisory board for Roche and Novartis.